Bioage Labs Analyst Price Targets - Benzinga

Bioage Labs Inc

BIOANASDAQ

Trade with Public

Trade with Public

$5.95

-0.01-0.17%

Ult. Agg.: Nov 5, 2:56 AM

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta Opzioni Rapporto azionario

Bioage Labs Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bioage Labs (BIOA).

Price Target Range — 7 Quarters

Analyst Consensus — 9 Analysts

7Buy

2Hold

Consensus RatingBuy# Analysts9Avg. Consensus PT$41Upside to Avg. PT+585.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 12, 2026	UBS	Alice Nettleton	Initiate	Neutral	$8
Sep 9, 2026	Roth Capital	Adam Walsh	Maintained	Buy	$25
Sep 8, 2026	BTIG	Thomas Shrader	Maintained	Buy	$40
Aug 6, 2026	BTIG	Thomas Shrader	Maintained	Buy	$40
Aug 3, 2026	BTIG	Thomas Shrader	Maintained	Buy	$40
Jul 31, 2026	Needham	Joseph Stringer	PT Cut	Buy	$50→$35
May 27, 2026	Roth Capital	Adam Walsh	Initiate	Buy	$36
May 13, 2026	BTIG	Thomas Shrader	Initiate	Buy	$40
Mar 27, 2026	Needham	Joseph Stringer	Initiate	Buy	$50
Mar 10, 2026	Citigroup	Samantha Semenkow	PT Raise	Buy	$15→$52
Feb 25, 2026	Oppenheimer	Jay Olson	Initiate	Outperform	$60
Feb 18, 2026	Jefferies	Roger Song	Upgrade	Hold→Buy	$9→$62
Jan 27, 2026	Piper Sandler	Yasmeen Rahimi	Initiate	Overweight	$73
Dec 8, 2025	Morgan Stanley	Jeffrey Hung	Upgrade	Underweight→Equal-Weight	$5→$12
Oct 29, 2025	Citigroup	Samantha Semenkow	PT Raise	Buy	$10→$15
Oct 22, 2025	Citigroup	Samantha Semenkow	Upgrade	Neutral→Buy	$5→$10
Mar 24, 2025	Citigroup	Samantha Semenkow	PT Cut	Neutral	$7→$5
Mar 7, 2025	Morgan Stanley	Jeffrey Hung	Assumes	Underweight	$5
Feb 28, 2025	William Blair	Andy Hsieh	Initiate	Market Perform	—
Dec 9, 2024	Citigroup	Samantha Semenkow	Downgrade	Buy→Neutral	$45→$7

Analyst Ratings News

PRO
UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8

UBS analyst Alice Nettleton initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Neutral rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Roth Capital Reiterates Buy on Bioage Labs, Maintains $25 Price Target

Roth Capital analyst Adam Walsh reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target

BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target

BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Bioage Labs, Maintains $40 Price Target

BTIG analyst Thomas Shrader reiterates Bioage Labs (NASDAQ:BIOA) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
Needham Maintains Buy on Bioage Labs, Lowers Price Target to $35

Needham analyst Joseph Stringer maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the price target from $50 to $35.

Benzinga Newsdesk